AUPH News and Press, Aurinia Pharmaceuticals Inc From 05/17/19

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “ Company ”) today announced that Mr. Peter Greenleaf, Chief Executive Officer, will present a corporate overview at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 22, 2019 at 6:30am PT (9:30am ET...

Aurinia Pharmaceuticals, Inc. (AUPH) Q1 2019 Earnings Conference Call May 14, 2019 4:30 PM ET Company Participants Glenn Schulman - Investor Relations Richard Glickman - Emeritus Chairman & Chief Executive Officer Peter Greenleaf - Chief Executive Officer Dennis Bourgeault ...

Aurinia Pharma (NASDAQ: AUPH ): Q1 GAAP EPS of -$0.14 beats by $0.01 . Revenue of $0.03M in-line (flat Y/Y). Cash and equivalents of $144.3M. Press Release More news on: Aurinia Pharmaceuticals Inc., Earnings news and commentary, Healthcare stocks news,

- Conference call and webcast to be hosted today at 4:30pm EDT - Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today reported financial results for the first quarter ended March 31, 2019 and provided an update on recent op...

Market Assessment 2019 could be a transformational year for Aurinia Pharmaceuticals (AUPH) from being a clinical-stage small-cap ($573M) to commercial stage biopharma, if the ongoing Phase 3 study of voclosporin (formerly ISA247) in patients with lupus nephritis ((LN)) achieves its primary...

In recognition of Lupus Awareness Month and World Lupus Day, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP) (the “Company”) a late clinical-stage biopharmaceutical company with ongoing research in lupus nephritis (“LN”), today recognized World Lupus Day and Lu...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “ Company ”) today announced that it will release its first quarter 2019 financial results on Tuesday, May 14, 2019, after the market closes. Aurinia’s management team will host a conference call to discuss the co...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced it has appointed Dr. Daniel Billen to its Board of Directors. Dr. Billen’s...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “ Company ”) today announced that members of the management team will present a corporate overview at the 2019 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 30, 2019 at 8:30am PT (11:30am ET) in...

Aurinia Pharmaceuticals ( AUPH -2.9% ) appoints Peter Greenleaf as CEO of the company and Director More news on: Aurinia Pharmaceuticals Inc., Healthcare stocks news, Read more ...